X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.
Lead Product(s): Egineered Treg Cell Therapy
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $1,900.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2022
Details:
Funding will advance novel pipeline of best-in-class engineered regulatory T cell therapies to durably restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.
Lead Product(s): Engineered Regulatory T Cell Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Matrix Capital Management
Deal Size: $157.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
